Differential anti-thrombotic benefit and bleeding risk profiles of antagonists of protease-activated receptor 1 and 4 in Cynomolgus Macaques-Reference-Cited by-同舟云学术

Differential anti-thrombotic benefit and bleeding risk profiles of antagonists of protease-activated receptor 1 and 4 in Cynomolgus Macaques

Published:2016-09 Issue: Volume:145 Page:133-139
ISSN:0049-3848
Container-title:Thrombosis Research
language:en
Short-container-title:Thrombosis Research

Author:

Wickham L. Alexandra,Sitko Gary,Stranieri-Michener Maria,Handt Larry,Basso Andrea,Fried Steven,Chu Lin,Maderia Maria,Owens Karen,Castriota Gino,Chen Zhu,Metzger Joseph M.,Imbriglio Jason,Wang Xinkang,Cai Tian-Quan

Funder

Merck

Publisher

Elsevier BV

Subject

Hematology

Reference32 articles.

1. Current antiplatelet therapies: benefits and limitations;Angiolillo;Am. Heart J.,2008

2. Platelet thrombin receptor antagonism and atherothrombosis;Angiolillo;Eur. Heart J.,2010

3. Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar;Baker;Circulation,2014

4. Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist;Cai;Eur. J. Pharmacol.,2015

5. Platelet protease-activated receptor (PAR)4, but not PAR1, associated with neutral sphingomyelinase responsible for thrombin-stimulated ceramide-NF-κB signaling in human platelets;Chen;Haematologica,2013

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lead Optimization to Advance Protease-Activated Receptor-1 Antagonists in Early Discovery;Journal of Medicinal Chemistry;2022-03-29

2. SePARating thrombosis and hemostasis?;Thrombosis Research;2016-09